BACKGROUND: Trials demonstrating the efficacy of biologic therapy for moderate to severe @entity1751 ( @entity1751 ) have inspired new multidisciplinary treatment strategies. We present our experience with combined biologic and surgical therapy for recalcitrant @entity1751 . METHODS: Between 2011 and 2014, 21 @entity1 (57 cases) with Hurley Stage III @entity1751 underwent radical resection with delayed primary closure alone, or in combination with adjuvant biologic therapy. Demographic data, treatment regimen, outcomes, and complications were retrospectively reviewed for all cases. RESULTS: Eleven @entity1 underwent combined surgical and biologic therapy, whereas radical resection alone was performed in 10 @entity1 . The average soft tissue deficit, before closure, for the combined and surgery-only @entity1 was 56 cm and 48.5 cm, respectively (P = 0.66). Biologic agents including infliximab (n = 8) and ustekinumab (n = 3) were initiated 2 to 3 weeks after closure and were continued for an average of 10.5 months. Recurrence was noted in 19% (4/29) and 38.5% (10/26) of previously treated sites for combined and surgery-only @entity1 (P < 0.01). For the combined cohort, the disease-free interval was approximately 1 year longer on average (P < 0.001); however, this difference was reduced to 4.5 months when considering time to recurrence after cessation of biologic therapy (P = 0.09). New disease developed in 18% (2/11) and 50% (5/10) of combined and surgery-only @entity1 , respectively (P < 001). No adverse events were noted among @entity1 who received biologic therapy. CONCLUSIONS: Lower rates of recurrence and disease progression, as well as a longer disease-free interval may be achieved with the use of adjuvant biologic therapy after radical resection for recalcitrant @entity1751 .

Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1751 :: ('MESH:D017497', 'Disease') :: ['HS', 'hidradenitis suppurativa']
@entity1751 :: (MESH:D017497,Disease) :: ['Hidradenitis Suppurativa']
